Royalty Pharma (RPRX) Income from Continuing Operations (2019 - 2026)

Royalty Pharma has reported Income from Continuing Operations for 8 years, with the latest figure at 468256000.0 in Q1 2026.

• Quarterly Income from Continuing Operations rose 7.79% year-over-year to 468256000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1359015000.0 (down 23.2% YoY) and the FY2025 annual result came in at 1324192000.0, changed 0.5% from the prior year.
• Income from Continuing Operations improved to 468256000.0 in Q1 2026 per RPRX's latest filing, from 355913000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 806358000.0 in Q3 2024 and troughed at 610030000.0 in Q4 2022.
• A 5-year average of 297318411.76 and a median of 351336000.0 in 2023 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations plunged 1236.61% in 2022, then surged 10266.93% in 2025.
• Over 5 years, Income from Continuing Operations stood at 610030000.0 in 2022, then soared by 217.63% to 717586000.0 in 2023, then sank by 53.41% to 334351000.0 in 2024, then gained by 6.45% to 355913000.0 in 2025, then surged by 31.56% to 468256000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 468256000.0, 355913000.0, and 444211000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.